Literature DB >> 18855017

Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients.

Marie Westerlund1, Andrea Carmine Belin, Lars Olson, Dagmar Galter.   

Abstract

The membrane transporter multi-drug resistance 1 (MDR1, P-gp) regulates the bioavailability of endogenous and exogenous compounds and has been implicated in disorders such as Parkinson's disease, cancer, epilepsy, human immunodeficiency virus disease, and inflammatory bowel disease. To promote further understanding of the role of MDR1 in disease, we have characterized cellular MDR1 mRNA expression in post-mortem human and fresh-frozen Sprague-Dawley rat tissues by using radioactive oligonucleotide probe in situ hybridization. We report MDR1 mRNA in human and rat endothelial cells of small vessels in the brain and pia mater. Mdr1 mRNA is also expressed in the blood vessel walls of rat sensory dorsal root and sympathetic ganglia. In peripheral tissues, we have observed MDR1 mRNA in human and rat liver and renal tubules and in human adrenal cortex and the epithelial lining of rat intestine. In female and male reproductive tissues of rat, strong gene activity has been found in steroid-hormone-synthesizing cells. Quantification of MDR1 mRNA in human striatum has revealed reduced levels in Parkinson patients compared with control individuals. The high expression of MDR1 mRNA in blood vessels of the nervous system, in tissues involved in absorption and excretion, and in tissues forming barriers to the environment support the physiological role of MDR1 as a regulator of intracellular levels of endogenous and exogenous compounds.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855017     DOI: 10.1007/s00441-008-0686-5

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  11 in total

Review 1.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

2.  P-Glycoprotein Transport of Neurotoxic Pesticides.

Authors:  Sarah E Lacher; Kasse Skagen; Joachim Veit; Rachel Dalton; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

3.  Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein.

Authors:  Yasmine F Ibrahim; Rabab A Moussa; Asmaa M A Bayoumi; Al-Shaimaa F Ahmed
Journal:  Inflammopharmacology       Date:  2019-08-22       Impact factor: 4.473

Review 4.  Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders.

Authors:  Hisham Qosa; David S Miller; Piera Pasinelli; Davide Trotti
Journal:  Brain Res       Date:  2015-07-15       Impact factor: 3.252

5.  Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.

Authors:  Jens Pahnke; Pablo Bascuñana; Mirjam Brackhan; Katja Stefan; Vigneshwaran Namasivayam; Radosveta Koldamova; Jingyun Wu; Luisa Möhle; Sven Marcel Stefan
Journal:  Free Neuropathol       Date:  2021-12-13

6.  Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.

Authors:  Sarah E Lacher; Julia N Gremaud; Kasse Skagen; Emily Steed; Rachel Dalton; Kent D Sugden; Fernando Cardozo-Pelaez; Catherine M T Sherwin; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2013-12-02       Impact factor: 4.030

Review 7.  ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis.

Authors:  Michael Jablonski; David S Miller; Piera Pasinelli; Davide Trotti
Journal:  Brain Res       Date:  2014-08-28       Impact factor: 3.252

Review 8.  Glutathione metabolism and Parkinson's disease.

Authors:  Michelle Smeyne; Richard Jay Smeyne
Journal:  Free Radic Biol Med       Date:  2013-05-08       Impact factor: 7.376

9.  An in vivo microdialysis study of FLZ penetration through the blood-brain barrier in normal and 6-hydroxydopamine induced Parkinson's disease model rats.

Authors:  Jinfeng Hou; Qian Liu; Yingfei Li; Hua Sun; Jinlan Zhang
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

10.  Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease.

Authors:  Sandra Gellhaar; Dan Sunnemark; Håkan Eriksson; Lars Olson; Dagmar Galter
Journal:  Cell Tissue Res       Date:  2017-05-02       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.